KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Account Payables (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Change in Account Payables data on record, last reported at $1.3 million in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 42.84% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $7.9 million, up 44.97%, while the annual FY2024 figure was $2.7 million, 192.51% up from the prior year.
  • Change in Account Payables reached $1.3 million in Q3 2025 per NKTR's latest filing, up from -$3.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $7.3 million in Q4 2022 and bottomed at -$12.9 million in Q4 2021.
  • Average Change in Account Payables over 5 years is -$243947.4, with a median of $669000.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: tumbled 552.73% in 2023, then skyrocketed 748.79% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$12.9 million in 2021, then soared by 156.33% to $7.3 million in 2022, then decreased by 11.57% to $6.4 million in 2023, then plummeted by 42.72% to $3.7 million in 2024, then crashed by 65.27% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.3 million in Q3 2025, -$3.5 million in Q2 2025, and $6.4 million in Q1 2025.